Shots:

• The TGA authorization follows the recent data shared by EMA and Singapore Health Sciences Authority for remdesivir’s approval in EU- Singapore and- Japan for COVID-19 patients
• TGA’s approval was made within 2 weeks of the receipt of the submission while the provisional approval is based on preliminary data valid for 6 years. Additionally- the company plans filling full registration confirming the safety and efficacy of the drug to the TGA committee
• Remdesivir is an investigational drug targeted reduce hospitalization time for COVID-19 while the drug will be available for severely unwell- requiring oxygen or high-level support to breathe- and in-hospital care

Click here to read full press release/ article

Ref: Therapeutic Goods Administration | Image: Gilead